Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04775836
Other study ID # 2017YFC1310901
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2018
Est. completion date December 31, 2021

Study information

Verified date February 2021
Source Ministry of Science and Technology of the People´s Republic of China
Contact Meng Wang, PhD
Phone 13261053863
Email wangmengpumc@163.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

In this protocol, the investigators present methods and preliminary results from the PLATFORM-CVD Study, an EHR-based multicenter cohort. This study will focus on assessing the distribution of major cerebrovascular diseases, determining the risk factors associated with disease incidence and worse in-hospital outcomes, as well as describing the quality of care. Data from this cohort will be used to develop suitable prediction models for cerebrovascular diseases using real-world data and to understand how outcomes for cerebrovascular diseases would change with quality improvement interventions.


Description:

Adherence to healthcare quality measures is needed to reduce the burden of cerebrovascular disease and improve clinical outcomes. Electronic health records (EHRs) can facilitate the standardization of care provision and the improvement of disease prediction and prevention. Although the EHRs in clinical settings are increasingly prevalent in China, they are rarely used for healthcare research. the investigators aimed to conduct an EHR-based registry study to improve the healthcare and outcomes for cerebrovascular diseases. Twenty-four hospitals were enrolled in the PLATFORM-CVD Study in January 2018. Data collection began on February 1st, 2019. Historical data from January 2017 are abstracted first and prospective data are continuously reported until May 20th, 2020. Data were abstracted from the medical records, including hospital information system, laboratory information management system, and picture archiving and communication systems by an extract-transform-load tool. The EHR system included diagnostic information for cerebral infarctions (I63), nontraumatic intracerebral hemorrhages (I61), nontraumatic subarachnoid hemorrhages (I60), transient cerebral ischemic attacks and related syndromes (G45), intracranial and intraspinal phlebitis and thrombophlebitis (G08), vascular dementia (F01), and other aneurysms (I72). The quality of stroke care was assessed by 21 evidence-based performance measures. In-hospital outcomes were calculated including mortality, length of stay, and costs. The PLATFORM-CVD Study leverages EHRs to better understand incident cerebrovascular diseases in China. Data from this cohort will serve as a unique platform for quality assessment and improvement for acute treatment and secondary prevention of cerebrovascular diseases, as well as in-hospital outcome risk predictions and health economic evaluations.


Recruitment information / eligibility

Status Recruiting
Enrollment 300000
Est. completion date December 31, 2021
Est. primary completion date December 31, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients were included in the registry if they were hospitalized with a primary diagnose of: - cerebral infarction (I63) - nontraumatic intracerebral hemorrhage (I61) - nontraumatic subarachnoid hemorrhage (I60) - transient cerebral ischemic attack and related syndromes (G45) - intracranial and intraspinal phlebitis and thrombophlebitis (G08) - vascular dementia (F01) - other aneurysms (I72) Exclusion Criteria: - Patients diagnosed with other diseases.

Study Design


Locations

Country Name City State
China Beijing Tiantan Hospital Beijing Beijing

Sponsors (24)

Lead Sponsor Collaborator
Ministry of Science and Technology of the People´s Republic of China Chinese Traditional Medicine Hospital of Meishan, Chongqing Donghua Hospital, Dalian Jiuzhou Century Hospital, Dengzhou Central Hospital, Guangdong Second Provincial General Hospital, Guangxi Ruikang Hospital, Handan Central Hospital, Hexigten Banner Mongolian Traditional Chinese Medicine Hospital, Inner Mongolian Hospital of Traditional Chinese Medicine, Kaifeng Central Hospital, Laoling People's Hospital, Mengjin People's Hospital, Nanyang Central Hospital, New Area People's Hospital of Luoyang, Renqiu Kangjixintu Hospital, Shenzhen Second People's Hospital, The Affiliated Hospital of Qingdao University, The Second Affiliated Hospital of Luohe Medical College, Wuhan No.1 Hospital, Xingtai City Ninth Hospital, Xunxian People's Hospital, Yilong People's Hospital, Yongcheng City Central Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary In-hospital mortality Patients who died during hospitalization due to cerebrovascular diseases From date of hospitalization until the date of discharge, assessed up to 90 days
Primary Length of stay at hospital The total days for a patients with cerebrovascular diseases at hospitalization From date of hospitalization until the date of discharge, assessed up to 90 days
Primary Costs The total costs for a patients with cerebrovascular diseases at hospitalization From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of antiplatelet medication use Rate of antiplatelet therapy during hospitalization From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of dual antiplatelet medication use for non-disabling IS and TIA events Rate of aspirin and clopidogrel therapy for ischemic cerebrovascular diseases (IS or TIA) during hospitalization From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of DVT prophylaxis = 48 hours Patients at risk for DVT (non-ambulatory) who received DVT prophylaxis by end of hospital 48 hours, including pneumatic compression, warfarin sodium, and novel oral anticoagulant 48 hours within hospitalization
Secondary Cerebrovascular assessment = seven days Cerebrovascular assessment (TCD, IVUS, brain CT or MR scan) within seven days of hospitalization 7 days within hospitalization
Secondary Statin therapy for LDL =100 mg/dL during hospitalization Lipid lowering agent prescribed during hospitalization if LDL = 100 mg/dL, if patient treated with lipid lowering agent prior to admission, or LDL not documented From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of anticoagulation medication use for atrial fibrillation during hospitalization Anticoagulation prescribed during hospitalization in patients with documented atrial fibrillation From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of antithrombotic medication prescribtion at discharge Antithrombotic therapy prescribed at discharge, including antiplatelet or anticoagulant therapy From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of antihypertensive medication prescribtion for patients with hypertension at discharge Antihypertension medication prescribed at discharge for patients with history of hypertension disease or hypertension disease documented during the hospitalization From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of statin prescribtion for low-density lipoprotein=100 mg/dL at discharge Lipid lowering agent prescribed at discharge if LDL = 100 mg/dL, if patient treated with lipid lowering agent prior to admission, or LDL not documented From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of hypoglycaemia medication prescribtion for diabetes mellitus at discharge Hypoglycemic medication prescribed at discharge for patients with history of diabetes mellitus or diabetes mellitus documented during the hospitalization From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of anticoagulation medication prescribtion for atrial fibrillation at discharge Anticoagulation prescribed at discharge in patients with documented atrial fibrillation From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of thrombolytic therapy Intravenous r-tPA in IS patients From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of thrombectomy therapy Thrombectomy therapy for IS patients From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of DVT prophylaxis = 48 hours for ICH Patients with ICH at risk for DVT (non-ambulatory) who received DVT prophylaxis by end of hospital 48 hours, including pneumatic compression. 48 hours within hospitalization
Secondary Rate of antihypertensive medicine use for ICH patients with hypertension at discharge Antihypertension medication prescribed at discharge for ICH patients with history of hypertension disease or hypertension disease documented during the hospitalization From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of hypoglycemia medication use for ICH patients with diabetes mellitus at discharge Hypoglycemic medication prescribed at discharge for ICH patients with history of diabetes mellitus or diabetes mellitus documented during the hospitalization From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of neurosurgery for ICH patients Neurosurgery of ICH include removal of hematoma by craniotomy, aspiration of hematoma by drilling, decompressive craniectomy, ventriculocentesis and drainage, other removal of intracranial hematoma From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of DVT prophylaxis = 48 hours for SAH Patients with SAH at risk for DVT (non-ambulatory) who received DVT prophylaxis by end of hospital 48 hours, including pneumatic compression 48 hours within hospitalization
Secondary Rate of antihypertensive medicine use for SAH patients with hypertension at discharge Antihypertension medication prescribed at discharge for SAN patients with history of hypertension disease or hypertension disease documented during the hospitalization From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of hypoglycemia medication use for SAH patients with diabetes mellitus at discharge Hypoglycemic medication prescribed at discharge for SAH patients with history of diabetes mellitus or diabetes mellitus documented during the hospitalization From date of hospitalization until the date of discharge, assessed up to 90 days
Secondary Rate of neurosurgery for SAH patients Neurosurgery of SAH include aneurysm clipping, endovascular embolization of aneurysm, extraventricular shunt From date of hospitalization until the date of discharge, assessed up to 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05993221 - Deconstructing Post Stroke Hemiparesis